Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.
Salman R. Punekar, MD
Advertisement
Articles by Salman R. Punekar, MD
Salman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5